title: Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy.
authors.affiliation: Department of Ophthalmology, Medical University of Vienna, Vienna, Austria2Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
authors.forename: Marion R
authors.initials: MR
authors.lastname: Munk
authors.affiliation: Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
authors.forename: Joshua
authors.initials: J
authors.lastname: Fernandes
authors.affiliation: Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
authors.forename: Marilyn
authors.initials: M
authors.lastname: Mets
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
authors.forename: Jyoti D
authors.initials: JD
authors.lastname: Patel
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
authors.forename: Melissa L
authors.initials: ML
authors.lastname: Johnson
authors.affiliation: Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
authors.forename: Lee M
authors.initials: LM
authors.lastname: Jampol
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D001323:Autoantibodies / Q000097:blood; D001324:Autoantigens / Q000276:immunology; D004596:Electroretinography; D000069347:Erlotinib Hydrochloride; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D007262:Infusions, Intravenous; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009755:Night Blindness / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology*; D059545:Paraneoplastic Syndromes, Ocular / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology*; D010751:Phosphopyruvate Hydratase / Q000276:immunology; D011799:Quinazolines / Q000008:administration & dosage; D012118:Resorcinols / Q000008:administration & dosage / Q000009:adverse effects*; D012160:Retina / Q000187:drug effects; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology
chemical_list: C528044:5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide; D001323:Autoantibodies; D001324:Autoantigens; D018841:HSP90 Heat-Shock Proteins; D007555:Isoxazoles; D011799:Quinazolines; D012118:Resorcinols; D000069347:Erlotinib Hydrochloride; D010751:Phosphopyruvate Hydratase